Your browser doesn't support javascript.
loading
Treatment with trastuzumab deruxtecan in patients with HER2-positive breast cancer and brain metastases and/or leptomeningeal disease (ROSET-BM).
Niikura, Naoki; Yamanaka, Takashi; Nomura, Hironori; Shiraishi, Kazuhiro; Kusama, Hiroki; Yamamoto, Mitsugu; Matsuura, Kazuo; Inoue, Kenichi; Takahara, Sachiko; Kita, Shosuke; Yamaguchi, Miki; Aruga, Tomoyuki; Shibata, Nobuhiro; Shimomura, Akihiko; Ozaki, Yuri; Sakai, Shuji; Kiga, Yoko; Izutani, Tadahiro; Shiosakai, Kazuhito; Tsurutani, Junji.
Afiliação
  • Niikura N; Department of Breast Oncology, Tokai University School of Medicine, Kanagawa, Japan. niikura@is.icc.u-tokai.ac.jp.
  • Yamanaka T; Department of Breast and Endocrine Surgery, Kanagawa Cancer Center, Kanagawa, Japan.
  • Nomura H; First Department of Surgery, University of the Ryukyus, School of Medicine, Okinawa, Japan.
  • Shiraishi K; Department of Medical Oncology, Nagoya Medical Center, Nagoya, Aichi, Japan.
  • Kusama H; Department of Breast and Endocrine Surgery, Osaka International Cancer Institute, Osaka, Japan.
  • Yamamoto M; Department of Breast Surgery, Hokkaido Cancer Center, Hokkaido, Japan.
  • Matsuura K; Department of Breast Oncology, Saitama Medical University International Medical Center, Saitama, Japan.
  • Inoue K; Division of Breast Oncology, Saitama Cancer Center, Saitama, Japan.
  • Takahara S; Department of Breast Surgery, Kitano Hospital, Osaka, Japan.
  • Kita S; Department of Medical Oncology, National Cancer Center Hospital, Tokyo, Japan.
  • Yamaguchi M; Department of Breast Surgery, JCHO Kurume General Hospital, Fukuoka, Japan.
  • Aruga T; Department of Breast Surgery, Komagome Hospital, Tokyo, Japan.
  • Shibata N; Cancer Treatment Center, Kansai Medical University Hospital, Osaka, Japan.
  • Shimomura A; Department of Breast and Medical Oncology, National Center for Global Health and Medicine, Tokyo, Japan.
  • Ozaki Y; Department of Breast Oncology, Aichi Cancer Center Hospital, Nagoya, Aichi, Japan.
  • Sakai S; Department of Imaging Diagnosis and Nuclear Medicine, Tokyo Women's Medical University, Tokyo, Japan.
  • Kiga Y; Oncology Medical Science Department, Daiichi Sankyo Co., Ltd., Tokyo, Japan.
  • Izutani T; Oncology Medical Science Department, Daiichi Sankyo Co., Ltd., Tokyo, Japan.
  • Shiosakai K; Data Intelligence Department, Daiichi Sankyo Co., Ltd., Tokyo, Japan.
  • Tsurutani J; Advanced Cancer Translational Research Institute, Showa University, Tokyo, Japan.
NPJ Breast Cancer ; 9(1): 82, 2023 Oct 11.
Article em En | MEDLINE | ID: mdl-37821514
ABSTRACT
Therapeutic options for breast cancer patients with brain metastases (BM)/leptomeningeal carcinomatosis (LMC) are limited. Here, we report on the effectiveness and safety of trastuzumab deruxtecan (T-DXd) in human epidermal growth factor receptor 2-positive breast cancer patients with BM. Data were analyzed for 104 patients administered T-DXd. Overall response rate (ORR), progression-free survival (PFS), overall survival (OS), intracranial (IC)-ORR, and IC-PFS were evaluated. ORR by investigator assessment was 55.7% (total population). Median PFS was 16.1 months; 12-month OS rate was 74.9% (total population). Median time-to-treatment failure was 9.7 months. In 51 patients with BM imaging, IC-ORR and median IC-PFS by independent central review were 62.7% and 16.1 months, respectively. In 19 LMC patients, 12-month PFS and OS rates were 60.7% and 87.1%, respectively. T-DXd showed effectiveness regarding IC-ORR, IC-PFS, PFS, and OS in breast cancer patients with BM/active BM, and sustained systemic and central nervous system disease control in LMC patients.Trial Registration UMIN000044995.
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Idioma: En Ano de publicação: 2023 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Idioma: En Ano de publicação: 2023 Tipo de documento: Article